Detalhe da pesquisa
1.
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Gynecol Oncol
; 174: 239-246, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37236033
2.
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Int J Cancer
; 148(12): 3041-3050, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539540
3.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(8): 1124-1135, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257177
4.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Clin Cancer Res
; 28(1): 36-44, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34645648
5.
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Clin Pharmacokinet
; 57(4): 427-437, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063517
6.
Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
Clin Cancer Res
; 23(16): 4540-4544, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28442503